Viggle Inc. operates as a mobile and Web-based entertainment marketing platform for media companies, brands, and consumers in the United States. It guides users towards various forms of media consumption with television enhancement, music discovery, entertainment content publishing, and distributed viewing reminders. The company allows its consumers to play TV shows, share comments through social media, answer trivia questions or polls, chat with friends, play games, or discover more about the show, while watching TV through a free application that works on various types of mobile phones and tablets. Its users receive points for each check-in and engagement, such as poll, video quiz, game, or slide show and could redeem the points within the rewards catalog for items, including deals and offers, products, sweepstakes, charitable donations, select retail gift cards, and Viggle-branded and other merchandise. Viggle Inc., through its wetpaint.com, reports news stories and publishes information content covering top television shows, music, celebrities, entertainment news, and fashion. The company was formerly known as Function(x) Inc. and changed its name to Viggle Inc. in May 2012. Viggle Inc. was incorporated in 1994 and is headquartered in New York, New York.
Bio Blast Pharma Ltd., a clinical-stage biotechnology company, develops therapies for patients with rare and ultra-rare genetic diseases. Its products include Cabaletta, a mutant protein stabilizing platform based on a small repurposed molecule to treat oculopharyngeal muscular dystrophy, Machado Joseph disease or SCA3, and Kennedy's disease or SBMA; and BBrm, a read-through platform based on a small repurposed molecule that enables the read-through (or bypassing) of genetic defects called nonsense mutations or stop codons that interfere with normal protein formation to treat diseases caused by nonsense mutation. The company's products also comprise mPRT, a mitochondrial protein replacement platform based on biological fusion proteins to treat mitochondrial protein deficiency diseases (Friedrich's Ataxia and ornithine transcarbamylase deficiency) by replacing missing or mutated proteins into mitochondria, and restoring cell function. Bio Blast Pharma Ltd. was founded in 2012 and is headquartered in Tel Aviv, Israel.
Mecox Lane Limited designs and sells health and beauty products through various retail channels in the People's Republic of China. It offers beauty and healthcare products, including skin care, fragrance, cosmetics, and other personal care products. The company sells its products through its online platform and stores. The company was founded in 1996 and is headquartered in Shanghai, the People's Republic of China. As of May 20, 2014, Mecox Lane Limited operates as a subsidiary of Cnshangquan E-Commerce Co., Ltd.
Coronado Biosciences, Inc., a development stage biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The company's principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201, a biologic comprising the microscopic eggs of the porcine whipworm for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis, multiple sclerosis, autism, psoriasis, and type 1 diabetes; and CNDO-109, a biologic that activates the immune system's natural killer cells to seek and destroy cancer cells for the treatment of acute myeloid leukemia. Coronado Biosciences, Inc. has strategic alliances and commercial agreements with Ovamed GmbH, Dr. Falk Pharma GmbH, Freie Universitt Berlin, UCL Business PCL, and Progenitor Cell Therapy. The company was founded in 2006 and is based in Burlington, Massachusetts.
uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
NephroGenex, Inc., a pharmaceutical company, focuses on developing therapeutics to treat kidney disease. The company develops Pyridorin (pyridoxamine dihydrochloride), a therapeutic agent to slow the progression of diabetic nephropathy. It is also involved in studying the application of an intravenous formulation of Pyridorin for the treatment of specific types of acute kidney injury where pathogenic oxidative chemistries have been identified as a contributing factor to the severity of this condition. NephroGenex, Inc. was founded in 2004 and is headquartered in Research Triangle Park, North Carolina.
E2open, Inc. provides cloud-based, on-demand software solutions for supply chain management. The company delivers its software solutions on an integrated platform that enables companies to collaborate with their trading partners to procure, manufacture, sell, and distribute products. The company's E2open Business Network enables its customers to share product information, forecasts, inventory positions, sales orders, purchase orders, manufacturing work orders, quality and environmental data, shipments, invoices, and payments with their trading partners. Its products and services include E2 Analytics, which provides real-time data related to transformation, aggregation, and loading of standard business intelligence processes; E2 Planning & Response: Rapid Optimization that provide periodic, batch planning capabilities for network requirements planning and for network constrained planning; and E2 Planning & Response: Rapid Resolutions, which provides response planning capabilities so when change occurs planners can utilize what-if scenario planning to resolve demand and/or supply exceptions, as well as simulate events, such as promotions, new product introduction, and network changes. The company also offers E2 Process Management, a multi-enterprise software for demand, multi-tier, and supply processes; and E2 Cloud Connectivity, a multi-enterprise software for B2B integration that allows enterprises to integrate their internal applications and the applications of their trading partners through its E2open Business Network. In addition, it offers professional services, such as consulting, solution deployment, and B2B on-boarding services. The company sells its solutions directly, as well as through resellers and integrators primarily in the Americas, Europe, and Asia. It has a strategic alliance agreement with KPMG LLP. The company was founded in 2000 and is headquartered in Foster City, California.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering, developing, and commercializing therapies based on its proprietary, next-generation RNA interference (RNAi) platform. The company's lead product candidate, RXI-109, is a self-delivering RNAi compound, which is in Phase II clinical trial for use in the reduction of dermal scarring. Its therapeutic development programs in the discovery and preclinical stages include products for the treatment of ocular scarring, liver fibrosis, joint fibrosis, and vascular restenosis. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Hong Kong Television Network Limited is engaged in multimedia production and contents distribution, and other multimedia related activities in Hong Kong. The company produces dramas, variety and infotainment, and purchased content programs. It is also involved in the property investment activities; production, publishing, and licensing of musical works; and provision of management and agency services to artistes. The company was formerly known as City Telecom (H.K.) Limited and changed its name to Hong Kong Television Network Limited in January 2013. Hong Kong Television Network Limited was founded in 1992 and is headquartered in Kwai Chung, Hong Kong.
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that intends to enter Phase III clinical trials for immune thrombocytopenic purpura and a Phase II clinical trial for immunoglobulin A nephropathy; R348, a topical janus kinase/SYK inhibitor in Phase II clinical trials for the treatment of keratoconjunctivitis sicca or chronic dry eye; R118, an adenosine monophosphate-activated protein kinase activator that intends to enter Phase I clinical trial; and two oncology product candidates in Phase I development. It also has small molecule discovery programs in muscle wasting. Rigel Pharmaceuticals, Inc. has collaboration agreement Daiichi Sankyo to pursue research related to a specific target from a class of drug targets called ligases that control cancer cell proliferation through protein degradation; and a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.